Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 107Specimen Handling 78Magnetic Resonance Spectroscopy 69Carboplatin 67Cisplatin 66Biopsy 57Nivolumab 56Radiotherapy 49Cyclophosphamide 49Paclitaxel 48durvalumab 37Gemcitabine 37Radiation 36Dexamethasone 32olaparib 31Etoposide 31Rituximab 30Docetaxel 30Doxorubicin 28atezolizumab 27Ipilimumab 27Lenalidomide 26Taxes 25Pemetrexed 24Bevacizumab 24Vincristine 23Platinum 23Cytarabine 23Radiotherapy, Intensity-Modulated 22Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bupropion × 90 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡